HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis

Background HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. Methods Network meta-analysis of NA treatment-induced HBeAg seroconversion after 1–2 years of treatment was performed. In addition, NA treatment-induced HBeAg seroconversion after 3–5 years of treatment was systematically evaluated. Results A total of 31 articles were included in this study. Nine and five studies respectively reporting on 1- and 2-year treatment were included in our network meta-analysis. In addition, 6, 5, and 5 studies, respectively reporting on 3-, 4-, and 5-year treatment were included in our systematic evaluation. Telbivudine showed a significantly higher HBeAg seroconversion rate after a 1 year treatment period compared to the other NAs (odds ratio (OR) = 3.99, 95% CI 0.68–23.6). This was followed by tenofovir (OR = 3.36, 95% CI 0.70–16.75). Telbivudine also showed a higher seroconversion rate compared to the other NAs after a 2 year treatment period, (OR = 1.38, 95% CI 0.92–2.22). This was followed by entecavir (OR = 1.14, 95% CI 0.72–1.72). No significant difference was observed between spontaneous induction and long-term telbivudine treatment-induced HBeAg seroconversion. However, entecavir and tenofovir treatment-induced HBeAg seroconversions were significantly lower than spontaneous seroconversion. Conclusion Long-term treatment with potent anti-HBV drugs, especially tenofovir and entecavir, may reduce HBeAg seroconversion compared with spontaneous HBeAg seroconversion rate. Telbivudine treatment, whether short term or long term, is associated with higher HBeAg seroconversion compared with the other NAs. However, the high rates of drug resistance likely limit the application of telbivudine.

[1]  S. Locarnini,et al.  The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. , 2011, Journal of hepatology.

[2]  R. D. de Man,et al.  Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase , 2003, Gut.

[3]  Y. Liaw,et al.  Efficacy and safety of prolonged 3‐year telbivudine treatment in patients with chronic hepatitis B , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[4]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[5]  P. Hu,et al.  A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  Bao-en Wang,et al.  A 7‐year study of lamivudine therapy for hepatitis B virus e antigen‐positive chronic hepatitis B patients in China , 2009, Journal of digestive diseases.

[7]  J. Dixon,et al.  Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg‐positive chronic hepatitis B , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[8]  H. Zeng,et al.  Telbivudine Versus Entecavir for Nucleos(t)ide-Naive HBeAg-Positive Chronic Hepatitis B: A Meta-analysis , 2014, The American journal of the medical sciences.

[9]  C. Ferrari.  HBV and the immune response , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  S. Khakoo,et al.  Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors , 2015, Annals of gastroenterology.

[11]  H. Janssen,et al.  Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. , 2010, Gastroenterology.

[12]  T. Hu,et al.  Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[14]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[15]  YaYun Liu,et al.  Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. , 2014, World journal of gastroenterology.

[16]  Lanjuan Li,et al.  Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. , 2011, Antiviral research.

[17]  A. Bertoletti,et al.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Gut.

[18]  J. Niu,et al.  Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double‐blind trial , 2007, Hepatology.

[19]  M. Buti,et al.  TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS , 2008 .

[20]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[21]  C. Fidler,et al.  Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  T. Sriprayoon,et al.  Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[24]  W. Alexander,et al.  European Association for the Study of the Liver , 1968 .

[25]  Xiaoping Zhou,et al.  Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside‐naive Chinese chronic hepatitis B patients , 2010, Journal of viral hepatitis.

[26]  Yao Guang.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China , 2005 .

[27]  Y. Liaw.  HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B , 2009, Hepatology international.

[28]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[29]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[30]  Y. Liaw,et al.  Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B , 2012, Journal of viral hepatitis.

[31]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[32]  H. Ren,et al.  Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study , 2008, Hepatology international.

[33]  Hong Tang,et al.  A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study , 2011, Hepatitis monthly.

[34]  G.-Q. Wang,et al.  Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients , 2013, Journal of viral hepatitis.

[35]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[36]  T. Sriprayoon,et al.  Mo1833 Efficacy and Safety of Entecavir Versus Tenofovir Treatment in Chronic Hepatitis B Patients: A Randomized Controlled Trial , 2012 .

[37]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[38]  M. Pedroso,et al.  Comparative Efficacy of Oral Nucleoside or Nucleotide Analog Monotherapy Used in Chronic Hepatitis B: A Mixed‐Treatment Comparison Meta‐analysis , 2013, Pharmacotherapy.

[39]  W. London,et al.  Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. , 1997, The Journal of infectious diseases.

[40]  J. Kao,et al.  Improving clinical outcomes of chronic hepatitis B virus infection , 2015, Expert review of gastroenterology & hepatology.

[41]  S. Chen,et al.  Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial , 2015, Journal of viral hepatitis.

[42]  Jiyuan Zhang,et al.  Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection , 2012, Journal of gastroenterology and hepatology.

[43]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[44]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[45]  H. Ren,et al.  Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients , 2013, Hepatology International.

[46]  J. Stockman,et al.  Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B , 2010 .

[47]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[48]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[49]  M. Yuen,et al.  A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy , 2003, Gut.

[50]  A. Lok,et al.  Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 , 2006, Hepatology.

[51]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[52]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[53]  L. Mantovani,et al.  The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis , 2014, Systematic Reviews.

[54]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[55]  P. Lampertico,et al.  Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. , 2012, Gastroenterology.